A New Frontier in Alzheimer’s Research: Johns Hopkins Scientists Uncover Potential of a Brain-Boosting Gas

Researchers at Johns Hopkins Medicine are forging a promising new path in the fight against Alzheimer’s disease, thanks to a recently awarded grant from the National Institutes of Health (NIH). This significant funding is propelling forward a novel therapeutic approach centered on a seemingly unassuming protein within the brain that produces a minuscule, yet remarkably influential, gas. This gas, hydrogen sulfide, long recognized for its pungent aroma reminiscent of rotten eggs, is now being investigated for its critical role in the very mechanisms of memory formation and its potential to safeguard brain cells against neurodegenerative damage.

The protein at the heart of this groundbreaking research is known as Cystathionine gamma-lyase, or CSE. For years, CSE has been primarily associated with its role in generating hydrogen sulfide. However, emerging evidence, particularly from experiments conducted on genetically engineered mice, suggests that this gas plays a far more profound and beneficial function within the brain than previously understood. Dr. Bindu Paul, an associate professor of pharmacology, psychiatry, and neuroscience at the Johns Hopkins University School of Medicine and the lead investigator of the study, explained the significance of these findings, which were recently published in the prestigious journal Proceedings of the National Academy of Sciences. The research endeavors to unravel the intricate workings of CSE and to ascertain whether enhancing its activity could serve as a protective measure for neurons, thereby potentially slowing the progression of devastating neurodegenerative conditions like Alzheimer’s disease.

Unveiling the Neuroprotective Power of Hydrogen Sulfide

The notion that hydrogen sulfide might possess neuroprotective qualities is not entirely new. Prior studies had hinted at its ability to shield neurons in experimental models, specifically in mice. However, a significant hurdle to direct therapeutic application has been the inherent toxicity of hydrogen sulfide in higher concentrations, rendering its direct delivery to the brain unsafe. This inherent risk has steered the scientific community toward a more nuanced approach: understanding how to safely maintain the naturally occurring, extremely low levels of this gas within neurons.

The latest findings from the Johns Hopkins team provide compelling evidence for this delicate balance. Their experiments revealed that mice genetically engineered to lack the CSE enzyme exhibited marked deficits in memory and learning capabilities. Crucially, these CSE-deficient mice also displayed an increased burden of oxidative stress, significant DNA damage, and compromised integrity of the blood-brain barrier. These are all physiological hallmarks that are consistently observed in individuals afflicted with Alzheimer’s disease, according to Dr. Paul, who also serves as the corresponding author of the study. This correlation suggests a direct link between CSE function and the neuropathological changes characteristic of Alzheimer’s.

A Legacy of Discovery: Building on Decades of Research

The current research stands on the shoulders of pioneering work conducted over many years by Dr. Solomon Snyder, a professor emeritus of neuroscience, pharmacology, and psychiatry at Johns Hopkins. Dr. Snyder’s laboratory has been instrumental in advancing our understanding of gasotransmitters, a class of signaling molecules that includes hydrogen sulfide.

A pivotal study by Dr. Snyder’s team, published in Nature in 2014, demonstrated that CSE played a protective role in mice afflicted with Huntington’s disease, another debilitating neurodegenerative disorder. In those experiments, researchers utilized mice that lacked the CSE protein. This particular strain of mice had been developed earlier, in 2008, following the initial discovery of CSE’s involvement in the regulation of blood vessel function and blood pressure.

More recently, in 2021, Dr. Snyder’s group observed that CSE was not functioning optimally in mouse models of Alzheimer’s disease. Intriguingly, they found that administering very small, carefully controlled injections of hydrogen sulfide proved beneficial in protecting brain function in these models. While those earlier studies focused on mouse models that carried additional genetic mutations predisposing them to neurodegenerative diseases, the latest research meticulously isolates and examines the independent role of CSE itself.

"This most recent work indicates that CSE alone is a major player in cognitive function and could provide a new avenue for treatment pathways in Alzheimer’s disease," stated Dr. Snyder, who retired from the Johns Hopkins Medicine faculty in 2023. His continued involvement as a co-corresponding author underscores the enduring significance of his contributions to the field.

The Progressive Decline of Memory Linked to CSE Deficiency

To precisely delineate how CSE influences memory, the Johns Hopkins scientists employed a comparative approach. They meticulously examined mice that lacked the CSE protein against normal mice of the same genetic strain that had been developed in 2008. A key experimental tool in their investigation was the Barnes maze, a standard apparatus used to assess spatial memory—the ability of an animal to remember locations and navigate using environmental cues.

In the Barnes maze test, mice are tasked with locating a hidden escape shelter to evade a bright, aversive light. At the age of two months, both the normal mice and those deficient in CSE demonstrated comparable performance, successfully finding the shelter within a three-minute timeframe. However, a stark divergence emerged by the age of six months. The CSE-deficient mice began to struggle significantly in locating the escape route, indicating a decline in their spatial memory. In contrast, the normal mice continued to exhibit proficient navigation and escape.

"The decline in spatial memory indicates a progressive onset of neurodegenerative disease that we can attribute to CSE loss," remarked Dr. Suwarna Chakraborty, the first author of the study and a researcher in Dr. Paul’s laboratory. This progressive nature of the memory impairment in the absence of CSE strongly implicates the protein in maintaining long-term cognitive function.

Cellular and Structural Brain Changes Mirror Alzheimer’s Pathology

Beyond behavioral observations, the researchers delved into the cellular and structural alterations occurring within the brains of mice lacking CSE. The hippocampus, a brain region critically involved in learning and memory formation, relies heavily on the continuous generation of new neurons, a process known as neurogenesis. Disruptions in neurogenesis are a well-established characteristic of various neurodegenerative diseases, including Alzheimer’s.

Employing a battery of biochemical and analytical techniques, the team discovered that the expression levels of proteins essential for neurogenesis were significantly reduced or entirely absent in the brains of CSE-deficient mice. This finding points to a fundamental impairment in the brain’s capacity to generate new cells vital for cognitive function.

Further examination using high-powered electron microscopes revealed tangible structural damage within the brains of these mice. The scientists observed substantial breaks in blood vessels, indicative of damage to the blood-brain barrier. This compromised barrier is another hallmark feature observed in Alzheimer’s disease, where it can allow harmful substances to enter the brain and disrupt neuronal function. Moreover, the study noted that newly formed neurons in these mice encountered difficulties in migrating to the hippocampus, where their integration is crucial for effective memory consolidation.

"The mice lacking CSE were compromised at multiple levels, which correlated with symptoms that we see in Alzheimer’s disease," explained Dr. Sunil Jamuna Tripathi, a co-first author of the study and a researcher in Dr. Paul’s lab. This multifaceted impact underscores the pervasive role of CSE in maintaining brain health and function.

Implications for Future Alzheimer’s Therapies

Alzheimer’s disease represents a monumental public health challenge. In the United States alone, it affects more than 6 million individuals, a number projected to rise significantly in the coming years, according to the U.S. Centers for Disease Control and Prevention. Despite extensive research efforts, current therapeutic options have demonstrated limited success in consistently halting or even significantly slowing the progression of this devastating disease.

The findings from Johns Hopkins Medicine offer a beacon of hope. By illuminating the critical role of CSE and its production of hydrogen sulfide, this research opens up a compelling new avenue for the development of novel therapeutic strategies. The focus is on harnessing the protective potential of hydrogen sulfide, not by direct administration, but by devising ways to modulate CSE activity or its downstream signaling pathways to maintain optimal, low-level concentrations of the gas within the brain. Such therapies could potentially be designed to protect brain cells from the ravages of neurodegeneration and to slow the inexorable march of cognitive decline associated with Alzheimer’s.

A Collaborative Effort Fueled by Robust Funding

This groundbreaking research was made possible through substantial financial support from a consortium of prestigious funding bodies. The National Institutes of Health provided crucial backing through multiple grants, including R01AG071512, P50DA044123, 1R21AG073684, O1AGs066707, U01 AG073323, AG077396, NS101967, NS133688, and P01CA236778. Additional support came from the Department of Defense (HT94252310443), the American Heart Association, the AHA-Allen Initiative in Brain Health and Cognitive Impairment, the Solve ME/CFS Initiative, a Catalyst Award from Johns Hopkins University, the Valour Foundation, the Wick Foundation, a Department of Veterans Affairs Merit Award (I01BX005976), the Louis Stokes Cleveland Department of Medical Affairs Veterans Center, the Mary Alice Smith Funds for Neuropsychiatry Research, the Lincoln Neurotherapeutics Research Fund, the Gordon and Evie Safran Neuropsychiatry Fund, and the Leonard Krieger Fund of the Cleveland Foundation.

The multidisciplinary team responsible for this research includes not only Drs. Paul, Snyder, Chakraborty, and Tripathi from Johns Hopkins, but also Richa Tyagi and Benjamin Orsburn from Johns Hopkins. Collaborators from Case Western University include Edwin Vázquez-Rosa, Kalyani Chaubey, Hisashi Fujioka, Emiko Miller, and Andrew Pieper. Further contributions came from Thibaut Vignane and Milos Filipovic of the Leibniz Institute for Analytical Sciences in Germany, Sudarshana Sharma from Hollings Cancer Center, Bobby Thomas from Darby Children’s Research Institute and the Medical University of South Carolina, and Zachary Weil and Randy Nelson from West Virginia University School of Medicine. This extensive collaboration highlights the complex and global nature of modern scientific inquiry.

The implications of this research extend beyond Alzheimer’s, potentially offering new therapeutic avenues for other neurodegenerative conditions characterized by neuronal dysfunction and loss. As the scientific community continues to unravel the intricate roles of molecules like hydrogen sulfide in brain health, the prospect of developing more effective treatments for age-related cognitive decline and neurodegenerative diseases grows increasingly tangible. The ongoing work at Johns Hopkins Medicine represents a significant leap forward in that critical endeavor.